What does the evidence say about N-Acetylcysteine Oxidative Stress Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for N-Acetylcysteine Oxidative Stress Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Conclusion Our meta-analysis indicates that N-acetylcysteine, when compared to placebo, does not demonstrate consistent efficacy in reducing the primary symptoms of AUD or PTSD in broad patient populations. [Ahmed MAE (2026); evidence level 1] - Introduction Alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) are thought to be significant global contributors to the burden of mental illness. [Ahmed MAE (2026); evidence level 1] - According to recent WHO epidemiological estimates, 3.9% of people worldwide have experienced PTSD at some point in their lives; this number rises to roughly 5.6% among those who have experienced trauma. [Ahmed MAE (2026); evidence level 1] - This document consolidates existing evidence to this effect, and adds insights from practicing clinicians to guide about use of NAC in clinical practice. [Barne M (2026); evidence level 2] - Conclusion This consensus underscores the role of NAC in chronic respiratory diseases beyond its mucolytic properties and reiterates that NAC's antioxidant, anti-inflammatory, immunomodulatory and anti-biofilm properties provide significant clinical utility. [Barne M (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.